补体调节蛋白C4BP(β-)的非经典免疫调节活性限制狼疮性肾炎发展
本研究在狼疮倾向小鼠中评估经典途径补体抑制剂次要亚型C4BP(β-)的治疗效果。C4BP(β-)治疗可预防蛋白尿和清蛋白尿、显著减少抗dsDNA抗体形成、减轻肾小球IgG和C3沉积及凋亡细胞生成,组织学改善并提高生存率,疗效与环磷酰胺相当,但肾脏基因表达变化仅为环磷酰胺的十分之一。
要点
- C4BP(β-)可预防狼疮小鼠蛋白尿和清蛋白尿,减少抗dsDNA抗体。
- C4BP(β-)减轻肾小球IgG和C3沉积,组织学改善并提高生存率。
- C4BP(β-)疗效与环磷酰胺相当,但转录组扰动仅为后者的十分之一。
核心结论
- C4BP(β-)通过抗炎和免疫调节活性限制狼疮性肾炎发展,可考虑进一步临床开发用于系统性红斑狼疮患者。
研究设计与样本
- 在狼疮倾向小鼠中开展C4BP(β-)治疗研究,并以环磷酰胺为对照进行疗效和转录谱比较。
主要发现
- C4BP(β-)治疗预防蛋白尿和清蛋白尿,显著减少抗dsDNA抗体形成。
- C4BP(β-)减轻肾小球IgG和C3沉积及凋亡细胞生成,组织学改善并提高生存率。
- C4BP(β-)疗效与环磷酰胺相当,但肾脏基因表达变化为环磷酰胺的十分之一。
- C4BP(β-)下调活化T细胞、B细胞、炎症吞噬细胞和中性粒细胞相关转录本。
- C4BP(β-)通过系统和局部CXCL13下调预防老年狼疮肾炎小鼠异位淋巴结构新生。
临床怎么用
- C4BP(β-)可能作为狼疮性肾炎的高特异性免疫调节治疗候选,需进一步临床开发验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lupus nephritis is a chronic autoimmune-inflammatory condition that can lead to end-stage kidney disease. Presently available immunosuppressive treatments for lupus nephritis are suboptimal and can induce significant side effects. Recently, we characterized a novel immunomodulatory activity of the minor isoform of the classical pathway complement inhibitor, C4BP(β-). We show here that C4BP(β-) treatment prevented the development of proteinuria and albuminuria, decreased significantly the formation of anti-dsDNA antibodies and, locally, mitigated renal glomerular IgG and C3 deposition and generation of apoptotic cells. There was a consequent histological improvement and increased survival in lupus-prone mice. The therapeutic efficacy of C4BP(β-) was analogous to that of the broad-acting immunosuppressant cyclophosphamide. Remarkably, a comparative transcriptional profiling analysis revealed that the kidney gene expression signature resulting from C4BP(β-) treatment turned out to be 10 times smaller than that induced by cyclophosphamide treatment. C4BP(β-) immunomodulation induced significant downregulation of transcripts relevant to lupus nephritis indicating immunopathogenic cell infiltration, including activated T cells (Lat), B cells (Cd19, Ms4a1, Tnfrsf13c), inflammatory phagocytes (Irf7) and neutrophils (Prtn3, S100a8, S100a9). Furthermore, cytokine profiling and immunohistochemistry confirmed that C4BP(β-), through systemic and local CXCL13 downregulation, was able to prevent ectopic lymphoid structures neogenesis in aged mice with lupus nephritis. Thus, due to its anti-inflammatory and immunomodulatory activities and high specificity, C4BP(β-) could be considered for further clinical development in patients with systemic lupus erythematosus.
引用
- Luque A, Serrano I, Ripoll E, et al. Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis. Kidney Int. 2019. PMID: 31982108. doi:10.1016/j.kint.2019.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。